The first phase I clinical trial of ARG1 inhibition in combination with anti-PD-1 demonstrated only limited anti-tumor activity when studied in numerous solid tumors including non-small-cell lung cancer, gastric cancer, renal cell cancer, melanoma, and urothelial carcinoma [77]. This evidence concerns the gene ARG1 and neoplasm.